Predictors of long-term persistence on statins in a subsidized clinical population

Value in Health

Volumn 3, Issue 6, 2000, Pages 417-426

  Catalan, Vanessa S ^a   Lelorier, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adherence; Compliance; Discontinuation; Dyslipidaemia; HMG CoA reductase inhibitors; Persistence; Primary prevention; Secondary prevention

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SOCIAL MEDICINE;

EID: 0034515494     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2000.36006.x     Document Type: Article

References (14)

1. The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines
2. Discontinuation of antihyperlipidemic drugs - Do rates reported in clinical trials reflect rates in primary care settings?
3. Apparent discontinuation rates in patients prescribed lipid-lowering drugs
4. Comparison of efficacy and cost among lipid-lowering agents in patients with primary hypercholesterolemia
5. Persistence of use of lipid-lowering medications
6. Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols
7. Compliance with and efficacy of treatment with prevastatin and cholestyramine: A randomized study on lipid-lowering in primary care
8. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec
9. A chronic disease score from automated pharmacy data
10. Incontinence drug utilization patterns in Québec, Canada
11. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia
12. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)